Effect of hydrogen/oxygen therapy for ordinary COVID-19 patients: a propensity-score matched case-control study.
Yingying Zeng, Weijie Guan, Kai Wang, Zhijun Jie, Xu Zou, Xiaoping Tan, Xinyu Li, Xiaohua Chen, Xiaoting Ren, Junhong Jiang, Zeguang Zheng, Jindong Shi, Nanshan Zhong · BMC infectious diseases · 2023
Research-use notice
Independent study record
Each H2HUBB study page organizes source-linked research details for educational use. Interpretation should remain proportional to the study design, population, controls, and limitations.
H2HUBB TAKEAWAY
In subgroup analysis of patients received hydrogen/oxygen, patients aged < 55 years (p = 0.028) and without comorbidities (p = 0.002) exhibited a shorter hospitalization (median 10 days). These findings add human evidence that helps define the outcomes that did and did not change with molecular hydrogen in this study.
What the Findings Mean
H2HUBB reviewed how inhaled hydrogen gas affected the outcomes measured in 180 patients with respiratory diseases. In subgroup analysis of patients received hydrogen/oxygen, patients aged < 55 years (p = 0.028) and without comorbidities (p = 0.002) exhibited a shorter hospitalization (median 10 days).
What the Researchers Studied
The researchers studied 180 patients with respiratory diseases. The study used a randomized human clinical trial. The comparison condition was control condition or baseline measurements.
What Effects Did Molecular Hydrogen Have?
Total 180 patients were collected from 3 centers in China, including 42 patients received hydrogen/oxygen therapy and 138 patients received oxygen therapy on the basis of standard-of-care. Patients were eligible for enrollment in the hydrogen/oxygen therapy group if they inhaled hydrogen/oxygen (H₂ -O₂ ) within 3 days of admission. patients who inhaled H₂ -O₂ for at least 7 days during hospitalization was also eligible for this study. In subgroup analysis of patients received hydrogen/oxygen, patients aged < 55 years (p = 0.028) and without comorbidities (p = 0.002) exhibited a shorter hospitalization (median 10 days). The authors concluded that this study indicated that hydrogen/oxygen might be a useful therapeutic medical gas to enhance SpO2 and shorten length of hospitalization in patients with ordinary COVID-19.
Why These Findings Matter
This publication adds useful evidence about where molecular hydrogen did and did not change the measured outcomes, helping define the larger therapeutic evidence base.
How Strong Is This Evidence?
This is human clinical evidence from a randomized human clinical trial. H2HUBB interprets the findings in the context of the study design, sample, comparator, and measured outcomes rather than using one publication as a verdict on hydrogen therapy.
Technical Study Details
H2HUBB classifies this publication as human clinical study with human clinical evidence. The research population or model was 180 patients with respiratory diseases. The reported sample size was 180. The study used a randomized human clinical trial. The hydrogen delivery method was inhaled hydrogen gas.
Limitations and Safety
Reported limitations: Secondly, interpretation of the findings might be limited by the sample size the patients of the study included was relatively low. Besides, due to the emergency at the earliest stage of the epidemic outbreak, the unavailability of post-treatment laboratory data as well as the incompleteness of SpO 2 data were another limitation of this study, which led to the lack of sufficient evidence and weakened the strength of conclusion.
Original Study and H2HUBB Research Context
H2HUBB presents this source-grounded research record as one contribution to the broader molecular-hydrogen evidence base.